New Delhi, June 3 -- India is looking to give a significant boost to its production-linked incentives for drug manufacturing, particularly in terms of its ambition to reduce the domestic pharmaceutical industry's dependence on China for its raw materials.

The upgraded PLI scheme will include more molecules used in manufacturing key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs), according to a communication issued on 14 May by the department of pharmaceuticals, which Mint has reviewed.

Details such as allocation, capacity, and incentive ceiling for the upgraded drug PLI scheme are being worked on, adepartment official said, declining to be identified.

Key starting materials and drug intermed...